The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Sp31
HOW TO REJIG YOUR TPN WHEN THE DELIVERY IS LATE
Date
May 6, 2023
Explore related products in the following collection:
There have been numerous times in the past few years wherein natural or man-made disasters have impacted the production and supply chain of key constituents of both enteral and parenteral nutrition products. These have impacted individuals on total parenteral nutrition (TPN) and on tube feeds or children/infants that are exclusively fed formula or suffer from metabolic or allergic disorders that necessitate them being on certain medical foods/specialty formula. As a community gastroenterolgists have been asked to step up in these situations to advocate for and construct disaster management plans. Through this session we would like to raise awareness for these general issues and provide state of the art guidance for these specific issues pertinent to daily clinical practice.
LIVE STREAM SESSION
There have been numerous times in the past few years wherein natural or man-made disasters have impacted the production and supply chain of key constituents of both enteral and parenteral nutrition products…
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…